Supplementary materials

Table S1 : Results of immunodot assay, ELISA and indirect immunofluorescence on MDA5 transfected cells and HEp-2 cells for the 23 patients with anti-MDA5 positive dermatomyositis

Patient ID	Immunodot	Immunodot intensity	ELISA (U/mL)	IIF on MDA5 transfected cells (inverse dilution)	IIF pattern on HEp-2 cells
MDA5+ 1	positive	85	108	1350	MDA5 pattern
MDA5+ 2	positive	56	138	1350	MDA5 pattern
MDA5+ 3	Hpo	103	94	1350	Non-specific
MDA5+ 4	Hpo	114	143	12150	MDA5 pattern
MDA5+ 5	positive	85	119	4050	MDA5 pattern
MDA5+ 6	Hpo	103	105	1350	MDA5 pattern
MDA5+ 7	Hpo	112	181	4050	MDA5 pattern
MDA5+ 8	Hpo	179	153	12150	MDA5 pattern
MDA5+ 9	positive	46	91	4050	MDA5 pattern
MDA5+ 10	positive	44	159	12150	MDA5 pattern
MDA5+ 11	positive	31	100	4050	MDA5 pattern
MDA5+ 12	Hpo	175	142	12150	MDA5 pattern
MDA5+ 13	Hpo	140	147	12150	MDA5 pattern
MDA5+ 14	positive	39	109	1350	MDA5 pattern
MDA5+ 15	positive	76	135	1350	MDA5 pattern
MDA5+ 16	positive	38	155	4050	Non-specific
MDA5+ 17	positive	60	120	12150	MDA5 pattern
MDA5+ 18	Hpo	136	161	12150	MDA5 pattern
MDA5+ 19	positive	42	154	12150	Non-specific
MDA5+ 20	Hpo	127	140	12150	MDA5 pattern
MDA5+ 21	positive	72	98	450	MDA5 pattern
MDA5+ 22	positive	81	143	4050	Non-specific
MDA5+ 23	positive	74	66	0	MDA5 pattern

The IIF pattern on HEp-2 cells was termed "MDA5 pattern" when the characteristic cytoplasmic staining in rare clustered cells was observed. Otherwise, it was termed "Non-specific".
Abbreviations: Hpo: high positive, IIF: indirect immunofluorescence.

Table S2 : Clinical features of the three clinical subgroups made depending on the frequency of RP-ILD, cutaneous manifestations, ulcerations, Raynaud phenomenon and arthritis

	Group 1 (n=11)	**Group 2 (n=3)**	**Group 3 (n=9)**
Mean age ± SD (years)	61 ± 13	50 ± 13	46 ± 15
Women	6/11 (55%)	2/3 (67%)	5/9 (56%)
Clinical manifestations			
RP-ILD	11/11 (100%)	0 (0)	0 (0)
Cutaneous manifestations	9/11 (82%)	3/3 (100%)	9/9 (100%)
Ulcerations	4/11 (36%)	3/3 (100%)	0 (0)
Arthritis	6/11 (55%)	3/3 (100%)	8/9 (89%)
Raynaud phenomenon	2/11 (18%)	3/3 (100%)	0 (0)
Muscular damage	6/11 (55%)	3/3 (100%)	6/9 (67%)
Mortality rate	6/11 (55%)	0 (0)	1/9 (11%)

Abbreviations: RP-ILD: rapidly progressive interstitial lung disease